Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail
  • Print
  • Share
  • E-mail
-
 
Pediatric Labeling Date:  02/21/2008
 
Trade Name:  Humira
 
Generic Name or Proper Name (*):  adalimumab
 
Indications Studied:  Treatment of juvenile idiopathic arthritis
 
Label Changes Summary:  Indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA)in patients 4 years of age and older Has not been studied in children <4 years of age; there are limited data on treatment in children with weight <15 kg Safety and efficacy in pediatric patients for uses other than JIA have not been established Adalimumab was studied in 171 patients 4 - 17 years with polyarticular JIA. AEs were generally similar to those seen in adults. 45% of children experienced an infection while receiving adalimumab with or without concomitant MTX in the first 16 weeks of treatment. Serious infections were observed in 4% of patients within approximately 2 years of initiation of treatment Information on dose, AEs, lab abnormalities, PK parameters, immunogenicity, immunization needs and clinical study New indication
 
Product Labeling:  Labeling  Opens a new window
 
PREA(P):  P
 
Sponsor:  Abbott
 
NNPS:  FALSE'
 
Therapeutic Category:  Anti-inflammatory
 
-
-